Hernández Conde Marta, Llop Herrera Elba, de la Revilla Negro Juan, Pons Renedo Fernando, Fernández Puga Natalia, Martínez Porras José Luis, Trapero Marugan María, Cuervas-Mons Valentín, Sánchez Turrión Víctor, Calleja Panero José Luis
Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Spain.
Department of Gastroenterology and Hepatology,Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda.
Rev Esp Enferm Dig. 2016 Nov;108(11):716-720. doi: 10.17235/reed.2016.4211/2016.
The prevalence of portal vein thrombosis (PVT) in patients that have undergone liver transplantation (LT) is 9.7% (SD 4.5). The aim of our study was to determine the prevalence, assess the factors that are associated with PVT and clarify their association with prognosis in patients with liver cirrhosis (LC) and LT.
From 2005 to 2014, laboratory, radiological and surgical data were collected from patients with LC in our center who had undergone LT for the first time.
One hundred and ninety-one patients were included. The mean age was 55 (SD 9), 75.4% of patients were male and 48.7% had HCV. The Child-Pugh scores were A/B/C 41.9%/35.9%/25.5% and the MELD score was 15 (SD 6). Previous decompensations were: ascites (61.4%), hepatic encephalopathy (34.4%), variceal bleeding (25.4%), hepatocellular carcinoma (48.9%) and spontaneous bacterial peritonitis (SPB) (14.3%). The mean post-transplant follow-up was 42 months (0-113). PVT was diagnosed at LT in 18 patients (9.4%). Six patients were previously diagnosed using imaging tests (33.3%): 2 patients (11.1%) by DU and 4 patients (22.2%) by CT scan. All patients with PVT had DU in a mean time of 6 months before LT (0-44) and 90 patients (47.1%) had a CT scan in a median time of 6 months before LT (0-45). PVT was significantly related to the presence of SBP (33.3% vs 12.6%; p = 0.02) and lower levels of albumin (3.1g/dl vs 3.4g/dl; p = 0.05). MELD was higher in patients with PVT (16.6 vs 14.9; p = 0.3). There were no significant differences with regard to the need for transfusion of blood components. Moreover, the surgery time was similar in both groups. PVT correlated with a higher mortality in the first 30 days (8.8% vs 16.7%; p = 0.2).
Prior history of SBP and lower levels of albumin were identified as factors associated with PVT. The pre-transplant diagnosis rate is very low and the presence of PVT may have implications for short-term mortality.
肝移植(LT)患者门静脉血栓形成(PVT)的患病率为9.7%(标准差4.5)。我们研究的目的是确定肝硬化(LC)和LT患者中PVT的患病率,评估与PVT相关的因素,并阐明它们与预后的关系。
2005年至2014年,收集了我们中心首次接受LT的LC患者的实验室、影像学和手术数据。
纳入191例患者。平均年龄为55岁(标准差9),75.4%的患者为男性,48.7%的患者患有丙型肝炎病毒(HCV)。Child-Pugh评分A/B/C级分别为41.9%/35.9%/25.5%,终末期肝病模型(MELD)评分为15分(标准差6)。既往失代偿情况包括:腹水(61.4%)、肝性脑病(34.4%)、静脉曲张出血(25.4%)、肝细胞癌(48.9%)和自发性细菌性腹膜炎(SPB)(14.3%)。移植后平均随访时间为42个月(0 - 113个月)。18例患者(9.4%)在LT时被诊断为PVT。6例患者先前通过影像学检查确诊(33.3%):2例患者(11.1%)通过十二指肠超声(DU)确诊,4例患者(22.2%)通过CT扫描确诊。所有PVT患者在LT前平均6个月(0 - 44个月)进行了DU检查,90例患者(47.1%)在LT前中位时间6个月(0 - 45个月)进行了CT扫描。PVT与SPB的存在显著相关(33.3%对12.6%;p = 0.02)以及白蛋白水平较低(3.1g/dl对3.4g/dl;p = 0.05)。PVT患者的MELD评分较高(16.6对14.9;p = 0.3)。在血液成分输血需求方面无显著差异。此外,两组的手术时间相似。PVT与前30天较高的死亡率相关(8.8%对16.7%;p = 0.2)。
既往SPB病史和较低的白蛋白水平被确定为与PVT相关的因素。移植前诊断率非常低,PVT的存在可能对短期死亡率有影响。